Overall Score

Revenue Model

Primarily a discovery-stage antibody platform with revenue still limited relative to valuation.

Gross margin remains strong at 74.95%, but the business is not yet producing positive operating leverage.

Revenue per share is only 0.22, underscoring that monetization is still early.

Profitability

Operating performance remains deeply negative with EBIT margin at -304.58% and net margin at -248.83%.

ROIC is -14.95% and ROE is -17.49%, indicating the company is still destroying capital on a TTM basis.

High R&D intensity at 298.87% of revenue continues to pressure earnings.

Balance Sheet

Liquidity is very strong with a current ratio of 12.77 and quick ratio of 12.63.

Debt levels are modest, with debt-to-equity at 0.15 and debt-to-assets at 0.10.

Cash per share of 1.77 and working capital of 626.0M provide a substantial cushion for ongoing R&D spending.

Cash Generation

Free cash flow remains negative at -19.45M EV/FCF and FCF per share of -0.59.

Operating cash flow is also negative, with OCF margin at -233.82% and OCF per share at -0.51.

Cash conversion remains poor, reflected in a cash conversion cycle of 426.6 days.

Valuation

The stock trades at a very rich EV/Sales multiple of 52.75, which leaves little room for execution misses.

Negative earnings and cash flow make traditional earnings-based valuation metrics less useful.

A strong balance sheet partially offsets the premium valuation, but the shares still look expensive on sales.